# Eucalyptus

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/eucalyptus
Canonical HTML page: https://gethealthbrief.com/entity/eucalyptus

## Timeline

- **2026-02-24**: Global Market Reaction — Industry analysts note the deal as a major consolidation in the GLP-1 and telehealth sectors.
- **2026-02-23**: Payout Details Emerge — Former CCO Joe Harris confirms a payout exceeding $1 million, highlighting the impact on staff wealth.
- **2026-02-19**: Acquisition Announced — Hims & Hers officially announces the $1.6 billion buyout of Sydney-based Eucalyptus.

## Recent coverage (2 stories)

### Hims Q2 revenue hits $753M; Alcon eye care grows 7%
2026-08-18 00:45:06 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Hims & Hers posted 38% revenue growth and 2.89M subscribers while absorbing $81M in nonrecurring charges, and Alcon's core EPS rose 9% to $0.84. Telehealth demand and ocular health innovation are driving divergent profit outcomes.
Full story: https://gethealthbrief.com/story/health-hims-alcon-q2-2026-earnings

### Hims & Hers Acquires Eucalyptus for $1.6B in Global Telehealth Consolidation
2026-02-24 04:10:02 · Sentiment: Positive · Impact: 7/10 · Sources: 2

US telehealth leader Hims & Hers has finalized a $1.6 billion acquisition of Australian digital health startup Eucalyptus, marking a major expansion into the Asia-Pacific market. The deal, driven by the explosive growth of GLP-1 weight-loss treatments, creates over 100 employee millionaires and solidifies Hims & Hers' position as a global powerhouse in direct-to-consumer healthcare.
Full story: https://gethealthbrief.com/story/hims-hers-eucalyptus-acquisition-glp1-telehealth

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.